Royalty Report Sample Clauses

Royalty Report. Not later than thirty (30) days after the beginning of each calendar quarter of each year (a “Reporting Period”), Licensee shall deliver to Licensor a true and accurate report (a “Royalty Report”), giving particulars of the business conducted by Licensee during the preceding Reporting Period as are relevant to an accounting for Royalties and Sublicense Fees due under this Agreement. The Royalty Report shall include the following at a minimum: (i) the quantity of Licensed Products sold by Licensee; (ii) the revenues arising from sales of Licensed Products; (iii) the calculated Royalty due to Licensor; (iv) revenues generated by any Sublicense Agreements, identifying the sublicensee, the amount, and the basis of the calculations; and (v) any other revenues received from third parties. Simultaneously with the delivery of each Royalty Report, Licensee shall pay to Licensor the applicable Royalty and Sublicense Fee due, as set forth in Paragraph 3 above.

Royalty Report. The term “Royalty Report” shall have the meaning ascribed to such term as provided in Section 5.3.

Royalty Report. After the First Commercial Sale of a Collaboration Product for which royalties are due and payable by Cephalon, its Affiliates or Sublicensees hereunder, Cephalon shall provide Ambit with a royalty report on a quarterly calendar basis within ninety (90) days after the end of the calendar quarter to which such royalty report applies. Each such report shall state, separately for Cephalon, and each Affiliate and Sublicensee, the number, description, and aggregate Net Sales, on a country-by-country basis, and product-by-product basis during the calendar quarter during which a royalty is payable. Contemporaneously with the submission of the royalty reports Cephalon shall pay to Ambit all royalties due for such calendar quarter.

Royalty Report. After the First Commercial Sale of a Licensed Product, Avro shall prepare a report (the “Royalty Report”) at the end of each Quarterly Period, setting out the Gross Revenue, the Net Revenue (including an itemized statement of any permitted discounts, refunds and taxes deducted), the Sublicensing Revenue, and the number of Licensed Products sold, along with calculations of any Royalties and Sublicensing Fee that are payable to UHN. Royalty Reports shall be due within [***] of the end of the relevant Quarterly Period. If no payments are due for any Quarterly Period, then the Royalty Report shall so state.

Royalty Report. Each payment of Royalties and Additional Royalties, if applicable, shall be accompanied by a report (“Royalty Report”), in a form substantially similar to Attachment Q and approved by Licensor in Licensor’s reasonable discretion, showing for such quarter: (a) the total quantity of Licensed Products sold on a sku basis broken down according to geographic region and product category as indicated on Attachment D (“Product Category”) (with descriptions so that each individual Licensed Product can be identified by sku); (b) the total Net Sales value of Licensed Products on a sku basis broken down according to geographic region and Product Category (with descriptions so that each individual Licensed Product can be identified by sku); and (c) the amount of Royalties payable to Licensor from the foregoing information.

Royalty Report. The term “Royalty Report” is defined in Section 6.4 (Reports on Net Sales and Sublicensing Revenues).

Royalty Report. For each calendar quarter for which GNE has an obligation to make royalty payments, such payments shall be accompanied by a report that specifies for such calendar quarter the following information (“Net Sales Report”): (i) total Net Sales of all Licensed Products sold in the Territory; (ii) Net Sales on a country-by-country basis for all Licensed Products sold; (iii) the exchange rate used to convert Net Sales from the currency in which they are earned to United States dollars; and (iv) the total royalties due to Immunocore. If GNE is reporting Net Sales for more than one Licensed Product, the foregoing information shall be reported on a Licensed Product-by-Licensed Product basis. Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.

Royalty Report. Each royalty payment shall be accompanied by a statement which sets forth the following information: (i) Total quantities sold of Transgenic Oil and amount involved, specified on a country by country basis. (ii) Total amounts of any excise taxes, sales taxes, shipping costs, insurance, sales commissions, import/export duties, returns, credits and discounts used to arrive at Net Sales. (iii) Amounts of royalties payable specified in accordance with Section 4(a) and 4(d) above.

Royalty Report. During the term of this Agreement after the first sale to a Third Party of the first Licensed Product, ALGORX shall furnish or cause to be furnished to BRIDGE on a quarterly basis a written report or reports (the "Royalty Report") covering each calendar quarter (a "Royalty Period") showing (i) gross sales and Net Sales of all Licensed Products in each country of the Territory during the Royalty Period; and (ii) the royalties, payable in Dollars, which shall have accrued hereunder with respect to such Net Sales. Royalty Reports and any royalties owed BRIDGE shall be due sixty (60) days after the end of the Royalty Period to which they pertain. In the event that there are no royalties due in a Royalty Period, the Royalty Report shall so state.